These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1346731)

  • 41. OKT3 for primary therapy of the first rejection episode in kidney transplants.
    Tesi RJ; Elkhammas EA; Henry ML; Ferguson RM
    Transplantation; 1993 May; 55(5):1023-9. PubMed ID: 8497875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mycophenolate sodium dosing in combination with tacrolimus: pharmacokinetic evaluation of a novel regimen in de novo tacrolimus-treated kidney transplant patients.
    Pons B; Delavenne X; Mehdi M; Maillard N; Sauron C; Berthoux F; Alamartine E; Basset T; Mariat C
    Clin Nephrol; 2012 Jun; 77(6):425-31. PubMed ID: 22595383
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of different immunosuppressive strategies in recipients of kidneys from nonheart-beating donors.
    Sánchez-Fructuoso AI; Marques M; Conesa J; Ridao N; Rodríguez A; Blanco J; Barrientos A
    Transpl Int; 2005 May; 18(5):596-603. PubMed ID: 15819810
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Basiliximab and mycophenolate mofetil in combination with low-dose cyclosporine and methylprednisolone effectively prevent acute rejection in kidney transplant recipients.
    Kovac D; Kotnik V; Kandus A
    Transplant Proc; 2005 Dec; 37(10):4230-4. PubMed ID: 16387086
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
    Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
    J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sirolimus rescue therapy for refractory rejection in renal transplantation.
    Hong JC; Kahan BD
    Transplantation; 2001 Jun; 71(11):1579-84. PubMed ID: 11435968
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
    Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC
    Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
    Jirasiritham S; Sumethkul V; Mavichak V; Na-Bangchang K
    Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improved solitary pancreas transplant graft survival in the modern immunosuppressive era.
    Odorico JS; Becker YT; Groshek M; Werwinski C; Becker BN; Pirsch JD; Sollinger HW
    Cell Transplant; 2000; 9(6):919-27. PubMed ID: 11202579
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Combined immunosuppression of FK506 and RS-61443 in rat limb allotransplantation].
    Kang H; Hong GX; Wang FB; Chen ZB; Huang QS; Weng YX
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2003 May; 17(3):264-7. PubMed ID: 12822367
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil.
    Wüthrich RP; Weinreich T; Ambühl PM; Schwarzkopf AK; Candinas D; Binswanger U
    Nephrol Dial Transplant; 1999 Feb; 14(2):394-9. PubMed ID: 10069195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits.
    Etienne I; Toupance O; Bénichou J; Thierry A; Al Najjar A; Hurault de Ligny B; Le Meur Y; Westeel PF; Marquet P; François A; Hellot MF; Godin M
    Nephrol Dial Transplant; 2010 Sep; 25(9):3096-106. PubMed ID: 20299336
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts.
    Azuma H; Binder J; Heemann U; Schmid C; Tullius SG; Tilney NL
    Transplantation; 1995 Feb; 59(4):460-6. PubMed ID: 7878746
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
    Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
    de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
    Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.
    Lawen JG; Davies EA; Mourad G; Oppenheimer F; Molina MG; Rostaing L; Wilkinson AH; Mulloy LL; Bourbigot BJ; Prestele H; Korn A; Girault D;
    Transplantation; 2003 Jan; 75(1):37-43. PubMed ID: 12544868
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
    Chamienia A; Dębska-Ślizień A; Król E; Biedunkiewicz B; Rutkowski B
    Transplant Proc; 2014 Oct; 46(8):2714-8. PubMed ID: 25380901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
    Kagaya H; Miura M; Saito M; Habuchi T; Satoh S
    Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):631-6. PubMed ID: 20136638
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A short course of mycophenolate immunosuppression inhibits rejection, but not tolerance, of rat liver allografts in association with inhibition of interleukin-4 and alloantibody responses.
    Huang WH; Yan Y; Li J; De Boer B; House AK; Bishop GA
    Transplantation; 2003 Oct; 76(8):1159-65. PubMed ID: 14578746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.